Adjuvant Avelumab for High-Risk Patients with Early Triple-Negative Breast Cancer
Pier Franco Conte, MD, University of Padua, Padova, Italy, describes results from the phase 3 A-BRAVE trial evaluating avelumab as an adjuvant treatment for patients with early triple-negative breast cancer at high risk of relapse.
There was not a significant improvement of disease-free survival with avelumab for high-risk patients with early TNBC when compared with observation. However, there was a significant improvement in overall survival with avelumab.
Source:
Conte PF, Dieci MV, Bisagni G, et al. A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. Presented by 2024 ASCO Annual Meeting. May 31-June 4, 2024; Chicago, IL. Abstract #LBA500
